未登录

H

Henry S. Heine

university of florida

H指数:20

被引数:1,757

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tolfenpyrad Modulates Antibiotic Activity on Francisella novicida and Synergizes with Electron Transport Chain Inhibitors

托非尼拉德调节弗朗西斯菌属novicida的抗生素活性并与电子传递链抑制剂协同作用

ACS Infectious Diseases

IF3.8

2026-04-140

PRE

Teixobactin: A Resistance-Evading Antibiotic for Treating Anthrax

Teixobactin：一种用于治疗炭疽的耐药性规避抗生素

ACS INFECTIOUS DISEASES

IF3.8

2025-02-270

PRE

Evaluation of a potent LpxC inhibitor for post-exposure prophylaxis treatment of antibiotic-resistant Burkholderia pseudomallei in a murine infection model

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2025-01-312

PRE

Tolfenpyrad Derivatives Exhibit Potent Francisella-Specific Antibacterial Activity without Toxicity to Mammalian Cells In Vitro

ACS INFECTIOUS DISEASES

IF3.8

2024-10-020

PRE

Omadacycline is active in vitro and in vivo against ciprofloxacin-resistant Bacillus anthracis

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2024-09-042

OAAI

Tolfenpyrad displays Francisella-targeted antibiotic activity that requires an oxidative stress response regulator for sensitivity

MICROBIOLOGY SPECTRUM

IF3.8

2023-12-123

OAAI

The BALB/c Mouse Model for the Evaluation of Therapies to Treat Infections with Aerosolized Burkholderia pseudomallei

ANTIBIOTICS-BASEL

IF4.6

2023-03-035

OA

Gepotidacin is efficacious in a nonhuman primate model of pneumonic plague

SCIENCE TRANSLATIONAL MEDICINE

IF14.6

2022-06-017

PRE

In Vitro and In Vivo Characterization of Tebipenem, an Orally Active Carbapenem, against Biothreat Pathogens

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2021-04-199

OA

Validated Methods for Removing Select Agent Samples from Biosafety Level 3 Laboratories

EMERGING INFECTIOUS DISEASES

IF6.6

2020-11-010

OAAI

GC-072, a Novel Therapeutic Candidate for Oral Treatment of Melioidosis and Infections Caused by Select Biothreat Pathogens

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2019-12-015

OAAI

The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Bacillus anthracis Infection in BALB/c Mice and Cynomolgus Macaques

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2017-10-017

OA

Evaluation of Combination Drug Therapy for Treatment of Antibiotic-Resistant Inhalation Anthrax in a Murine Model

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2017-09-0114

OAAI

In Vitro Antibiotic Susceptibilities of Francisella tularensis Determined by Broth Microdilution following CLSI Methods

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2017-09-0118

OAAI

The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Francisella tularensis SCHU S4 Infection in BALB/c Mice and Cynomolgus Macaques

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2017-08-0112

OAAI

Natural History of Francisella tularensis in Aerosol-Challenged BALB/c Mice

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2016-03-016

OAAI

In Vitro Antibiotic Susceptibilities of Yersinia pestis Determined by Broth Microdilution following CLSI Methods

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2015-04-0128

OAAI

Evaluation of Imipenem for Prophylaxis and Therapy of Yersinia pestis Delivered by Aerosol in a Mouse Model of Pneumonic Plague

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2014-06-0110

OA

Natural History of Yersinia pestis Pneumonia in Aerosol-Challenged BALB/c Mice

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2013-05-0118

OAAI

Impact of Spores on the Comparative Efficacies of Five Antibiotics for Treatment of Bacillus anthracis in an In Vitro Hollow Fiber Pharmacodynamic Model

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2012-03-0118

OAAI